Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
暂无分享,去创建一个
M. Taniwaki | M. Ogura | K. Tobinai | D. Maruyama | T. Uchida | N. Uike | I. Choi | K. Ishizawa | K. Itoh | K. Ando | N. Shimada | Ken Kobayashi